This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.

Atlas Venture’s Bruce Booth believes the belt-tightening by biotechs in the past few years will presage a better financing outlook for companies, but the ripple effects will be felt for some time to come. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, the longtime biotech VC said that there are clear positive signs for biotech, with the XBI ETF bouncing back from its lows in the 60s, February’s robust follow-on financing market and a stream of M&A deals. “Everybody did belt-tightening the last few years,” said Booth. “So, you’re coming from a good place in terms of overall burn rates, and companies, I think, are in a good place to be financed by the next wave of investors.”

View full story: https://www.biocentury.com/article/651821

#biotech #pharma #biopharma #lifescience #TheBioCenturyShow 

00:00 - Intro
01:54 - Capital Markets
07:19 - How to Pitch a VC
12:12 - Obesity 
16:30 - New Modalities
22:28 - Industry Efficiency, AI

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.

On the tenth anniversary of a viral media campaign for access to an unapproved drug that extended a boy’s life, bioethicist Arthur Caplan reflected in an interview with The BioCentury Show on how the experience reshaped public views, corporate policies and legal requirements associated with providing access to unapproved therapies.
The wide-ranging conversation also touched on the need for scientists to receive communications training that could help reduce the impacts of medical disinformation, Caplan’s concerns about the lack of transparency about Neuralink Corp.’s experimental implantable brain chip, and the benefits of teaching biopharma CEOs about ethics.

View full story: https://www.biocentury.com/article/651502

#biotech #pharma #biopharma #TheBioCenturyShow 

00:00 - Intro
01:12 - Josh Hardy & Compassionate Use
13:27 - Ethics Training for the C-suite
16:16 - FDA
23:44 - Neuralink & Transparency

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.

In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited by the potential for AI to “create a language of biology,” is cautious about investing in China given increasing geopolitical tensions, and is convinced that the U.S. healthcare system could do a far better job of delivering on the promise of rapidly progressing science.
Nelsen, who has helped finance and create more than 150 companies, including 47 that have reached valuations exceeding $1 billion, discussed his conviction that focusing on creating transformational medicines, rather than looking for short-term gains, is a key to success in the life sciences.

View full story: https://www.biocentury.com/article/651502

#biotech #pharma #biopharma #TheBioCenturyShow 

00:00 - Intro
02:00 - The Promise of AI 
08:37 - The Inflation Reduction Act
15:50 - China
26:04 - Building Companies Around Big challenges

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.

Success for the Singapore biotech project will take a global network, one which Khoo Shih and other prominent drivers of the local ecosystem are keen to leverage to bring the right combination of talent, experience and capital to the growing hub. Speaking on The BioCentury Show, Khoo Shih, CEO of investment firm ClavystBio, laid out the strategy for capitalizing on the ascendant energy and attention being devoted to Singapore biotech. While the goal continues to be to create companies that solve global problems and have a global outreach, she said the path involves bringing in international life science investors from day one.

View full story: https://www.biocentury.com/article/651376

#biotech #biopharma #pharma #TheBioCenturyShow

00:00 – Intro
04:48 – ClavystBio
08:18 – Why Singapore
19:07 – 65Labs Incubator
23:20 – Growing the Ecosystem